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ABSTRACT
Rationale: Medical masks are commonly used by
sick individuals with influenza-like illness (ILI) to
prevent spread of infections to others, but clinical
efficacy data are absent.
Objective: Determine whether medical mask use by
sick individuals with ILI protects well contacts from
related respiratory infections.
Setting: 6 major hospitals in 2 districts of Beijing,
China.
Design: Cluster randomised controlled trial.
Participants: 245 index cases with ILI.
Intervention: Index cases with ILI were randomly
allocated to medical mask (n=123) and control arms
(n=122). Since 43 index cases in the control arm also
used a mask during the study period, an as-treated
post hoc analysis was performed by comparing
outcomes among household members of index cases
who used a mask (mask group) with household
members of index cases who did not use a mask
(no-mask group).
Main outcome measure: Primary outcomes
measured in household members were clinical
respiratory illness, ILI and laboratory-confirmed viral
respiratory infection.
Results: In an intention-to-treat analysis, rates of
clinical respiratory illness (relative risk (RR) 0.61, 95%
CI 0.18 to 2.13), ILI (RR 0.32, 95% CI 0.03 to 3.13)
and laboratory-confirmed viral infections (RR 0.97,
95% CI 0.06 to 15.54) were consistently lower in the
mask arm compared with control, although not
statistically significant. A post hoc comparison between
the mask versus no-mask groups showed a protective
effect against clinical respiratory illness, but not against
ILI and laboratory-confirmed viral respiratory
infections.
Conclusions: The study indicates a potential benefit
of medical masks for source control, but is limited by
small sample size and low secondary attack rates.
Larger trials are needed to confirm efficacy of medical
masks as source control.
Trial registration number: ACTRN12613000852752;
Results.
INTRODUCTION
Medical masks are commonly used in health-
care settings for two main purposes: (1) by
well healthcare workers (HCWs) to protect
them from infections transmitted by droplet
route and splash and spray of blood and
body fluids; and (2) by sick individuals to
prevent transmission to others (source
control).1 2 There are currently major gaps
in our knowledge about the impact of masks
on the transmission of respiratory infections.3
Most clinical trials have been focused on the
protection of the well wearer, rather than on
source control.3 Cloth and medical masks
were originally developed as source control
to prevent contamination of sterile sites by
the wearer in operating theatres (OTs);4 5
however, their effectiveness in preventing sur-
gical site infections is yet to be proven.6–8
Although masks are also widely used in the
community to prevent spread of infection
from sick and infectious people,4 9–12 the
majority of data on their use are observa-
tional and derived from outbreaks and
Strengths and limitations of this study
▪ Medical masks are commonly used to prevent
spread of infection from sick individuals to
others; however, data on the clinical efficacy of
this approach are sparse.
▪ A cluster-randomised control trial was conducted
to examine the efficacy of medical masks as
source control.
▪ The sample size was small and the study was
underpowered to detect a statistically significant
difference in outcome in the intention-to-treat
analysis.
▪ Removal of masks in the intervention arm during
meal times may have reduced efficacy and
biased the results towards the null.
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pandemics. Among the nine randomised controlled
trials (RCTs) in household and community settings until
now,3 only one examined the role of masks as source
control and was inconclusive.13 In other clinical trials,
masks were either used by both sick patients (index
cases as source control) and their household
members14–16 or only by household members.17–19 Most
of these studies failed to show any efficacy of mask use
in preventing spread of infections from the sick
individuals.
Masks are also used to prevent surgical site infections
in the OT,3 although most studies failed to show any effi-
cacy against this indication.6–8 20 Only one clinical trial
reported high infection rates after surgery if masks were
not used by the surgeon in the OT.21 Among the five
clinical trials in the healthcare setting to test the efficacy
of masks/respirators as respiratory protection,3 none
examined the use of masks as source control. Laboratory
studies generally support the use of medical masks to
prevent spread of infections from patients with influenza
and tuberculosis (TB) to their contacts.22–24
Mask use as source control in healthcare settings has
now been included in standard infection control precau-
tions during periods of increased respiratory infection
activity in the community, yet there is no clinical efficacy
evidence to support this recommendation. The aim of
this study was to determine whether medical mask use
by people in a community setting with influenza-like
illness (ILI) protects well contacts from infection.
METHODS
Design
An RCT was conducted in fever clinics in six major hos-
pitals in two districts of Beijing, China. The fever clinics
are outpatient departments for the assessment and treat-
ment of febrile patients. The recruitment of participants
was started on 18 November 2013 and completed on 20
January 2014. Adults who attended the fever clinic were
screened by hospital staff to identify if they were eligible
for the study. A study staff member approached eligible
patients when they presented in the clinic and invited
them to participate in the study. Recruited patients
meeting the case definition of ILI (see below) were
referred to as index cases, which was the first case in a
potential chain of infection transmission.
Eligibility
Patients aged 18 years and older (index cases) with ILI
(defined as fever ≥38°C plus one respiratory symptom
including cough, nasal congestion, runny nose, sore
throat or sneezes) who attended a fever outpatient clinic
during the study period, had no history of ILI among
household members in the prior 14 days and who lived
with at least two other people at home were recruited
for the study. ILI was used as a selection criterion to
achieve high specificity for index cases. Patients who
were unable or refused to give consent, had onset of
symptoms >24 hours prior to recruitment, were admitted
to hospital, resided in a household with <2 other
people, or had other ill household members at home
were excluded from the study.
Randomisation
After providing informed consent, 245 index cases were
included and randomly allocated to intervention (mask)
and control (no-mask) arms. A research team member
(YZ) performed the random allocation sequence using
Microsoft Excel and doctors enrolled the participants
randomly to intervention and control arms. Patients had
an equal chance to be in the either intervention or
control arm. One hundred and twenty-three index cases
and 302 household contacts were included in the mask
(source control) arm and 122 index cases and 295
household contacts were included in the control arm
(figure 1). Cases and their household contacts were
assigned together as a cluster to either the intervention
or control arm.
Intervention
The mask or no-mask intervention was applied to the
index cases and respiratory illness was measured in
household contacts. Index cases (patients with ILI) in
the intervention arm wore a medical mask at home.
Index cases were asked to wear a mask (3M 1817 surgical
mask) whenever they were in the same room as a house-
hold member or a visitor to the household. They were
allowed to remove their masks during meal times and
while asleep. Index cases were shown how to wear the
mask and instructed to wash their hands when donning
and doffing the mask. Index cases were provided with 3
Figure 1 Consort diagram of recruitment and follow-up.
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masks per day for 7 days (21 masks in total). They were
informed that they could cease wearing a mask once
their symptoms resolved. Index cases in the control arm
did not receive any intervention. Mask use by other
household members was not required and not reported.
Outcome measures
Respiratory illness outcomes were measured in house-
hold contacts of the index cases. Primary end points
measured in household contacts included: (1) clinical
respiratory illness (CRI), defined as two or more respira-
tory symptoms (cough, nasal congestion, runny nose,
sore throat or sneezes) or one respiratory symptom and
a systemic symptom (chill, lethargy, loss of appetite,
abdominal pain, muscle or joint aches); (2) ILI, defined
as fever ≥38°C plus one respiratory symptom; and (3)
laboratory-confirmed viral respiratory infection, defined
as detection of adenoviruses, human metapneumovirus,
coronaviruses 229E/NL63 and OC43/HKU1, parain-
fluenzaviruses 1, 2 and 3, influenza viruses A and B,
respiratory syncytial virus A and B, or rhinovirus A/B by
nucleic acid testing (NAT) using a commercial multiplex
PCR (Seegen, Seoul, Korea).25–27
If any respiratory or systemic symptoms occurred in
household members, index cases were instructed to notify
the study coordinator. Symptomatic household members
were asked to complete ‘sick follow-up’ questionnaires
and anyone who met the CRI definition was tested for
laboratory-confirmed viral respiratory infections.
Data collection and follow-up
At baseline, detailed clinical and demographic informa-
tion including household structure was collected from
index cases and their household members. This
included age, sex, smoking history, comorbidities, medi-
cations, hand washing practices, influenza vaccination
and normal practices around the use of masks.
Follow-up period (7 days): Each index case was asked
to keep a diary to record activities, symptoms and daily
temperatures for 7 days. Symptoms in the household
members were also recorded in the diary cards and
index cases were asked to report any symptom. The
index cases were asked to contact the study coordinator
if any of the following symptoms appeared in household
members: cough, nasal congestion, runny nose, sore
throat, sneezes, chill, lethargy, loss of appetite, abdom-
inal pain and muscle or joint aches. The study coordin-
ator then assessed the household member and
completed a follow-up survey. Samples were obtained
from all symptomatic cases. All index cases in the inter-
vention and control arms were also asked to document
compliance with mask use.26 27 Diary cards to record
mask use were given to each index case, and they were
asked to carry them during the day. Diary cards were
returned to the investigators at the end of the study. The
study coordinator also contacted index cases via tele-
phone on every alternate day to check whether any
household member developed symptoms. Assessors were
not blinded, because the intervention (mask wearing)
was visible. However, laboratory testing was blinded.
Sample collection and laboratory testing
Samples were collected from index patients at the time
of recruitment and from symptomatic household
members during follow-up. Household members were
provided with an information sheet and written consent
was sought before sampling. Only those household
members who provided consent were swabbed. If the
sick household member was aged <18 years, consent was
obtained from a parent or guardian. Swabs were taken
at the home by trained investigators.
Double rayon-tipped, plastic-shafted swabs were used
to swab both tonsillar areas and the posterior pharyngeal
wall of symptomatic participants. The swabs were then
transported immediately after collection to the Beijing
Centre for Disease Control (CDC) laboratories, or
stored at 4°C within 48 hours if transport was delayed.
Viral DNA/RNA was extracted from each respiratory
specimen using the Viral Gene-spin TM Kit (iNtRON
Biotechnology, Seoul, Korea) according to the manufac-
turer’s instructions. Reverse transcription was performed
using the RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas, Ontario, Canada) to synthesise cDNA.
Multiplex PCR was carried out using the Seeplex RV12
Detection Kit (Seegen, Seoul, Korea) to detect adeno-
viruses, human metapneumovirus, coronavirus 229E/
NL63 and OC43/HKU1, parainfluenzaviruses 1, 2 or 3,
influenza viruses A or B, respiratory syncytial virus A or B,
and rhinovirus A/B. A mixture of 12 viral clones was used
as a positive control template, and sterile deionised water
was used as a negative control. Viral isolation by Madin
Darby Canine Kidney (MDCK) cell culture was under-
taken for some of the influenza samples that were NAT
positive. Specimen processing, DNA/RNA extraction,
PCR amplification and PCR product analyses were con-
ducted in different rooms to avoid cross-contamination.
Sample size
In this cluster-randomised design, the household was the
unit of randomisation and the average household size was
three people. Assuming that the attack rate of CRI in the
control households was 16–20% (based on the results of
a previously published household mask trial),17 with a
5% significance level and 85% power and a minimum
relative risk (RR) of 0.5 (intervention/control), 385 parti-
cipants were required in each arm, which was composed
of 118 households and, on average, 3 members per
household. In this calculation, we assumed that the
intracluster correlation coefficient (ICC) was 0.1. An esti-
mated 250 patients with ILI were recruited into the study
to allow for possible index case dropout during the study.
Data analysis
Descriptive statistics were compared in the mask and
control arms and respiratory virus infection attack rates
were quantified. Data from the diary cards were used to
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calculate person-days of infection incidence. Primary end
points were analysed by intention to treat across the study
arms and ICC for clustering by household was estimated
using the clchi2 command in Stata.28 RRs were calculated
for the mask arm. The Kaplan-Meier survival curves were
generated to compare the survival pattern of outcomes
across the mask and control arms. Differences between
the survival curves were assessed through the log-rank
test. The analyses were conducted at the individual level
and HRs were calculated using the Cox proportional
hazards model after adjusting for clustering by household
by adding a shared frailty to the model. Owing to the
very few outcome events encountered, a multivariable
Cox model was not appropriate. We checked the effect of
individual potential confounders on the outcome variable
fitting univariable Cox models. Since there were 10 cases
of CRI, we included this variable in a multivariable
cluster-adjusted Cox model. Multivariate analyses were
not performed for ILI and laboratory-confirmed viruses
because of low numbers.
A total of 43 index cases in the control arm also used
a mask during the study period (at least 1 hour per day)
and 7 index cases in the masks arm did not use a mask
at all, so a post hoc sensitivity analysis was carried out to
compare outcomes among household members of index
cases who used a mask (hereafter ‘mask group’) with
those of index cases who did not use a mask (hereafter
‘no-mask group’). All statistical analyses were conducted
using Stata V.13 (StataCorp. Stata 12 base reference
manual. College Station, Texas, USA: Stata Press, 2011).
RESULTS
A total of 245 index patients were randomised into the
mask arm (n=123) or the control arm (n=122). The
mask arm had on average 2.5 household contacts per
index case (n=302), while the control arm had 2.4
household contacts per index case (n=295).
Characteristics of index cases and household members
are presented in table 1. There was no significant differ-
ence between arms, and most characteristics, including
medication use (data not shown), were generally similar.
Viruses were isolated from 60% (146/245) of index
cases. Influenza was the most common virus isolated
from 115 (47%) cases—influenza A—100, influenza B—
11 and influenza A and B—4. Other viruses isolated
from index cases were rhinovirus,13 NL6311 and C229E.7
More than one virus was isolated in 48 (20%) index
cases, including 17 coinfections with influenza.
Table 2 shows the intention-to-treat analysis. CRI was
reported in four (1.91/1000 person-days) household
members in the mask arm, compared with six house-
hold members (2.95/1000 person-days) in the control
arm (RR 0.65, 95% CI 0.18 to 2.29). Only one case
(0.48/1000 person-days) of ILI was reported in the mask
arm, compared with three cases (1.47/1000 person-days)
in the control arm (RR 0.32, 95% CI 0.03 to 3.11). Two
laboratory-confirmed infections were identified among
symptomatic household members from a separate house-
hold. One household member had the same infection
(influenza H1N1) as the respective index case.
Rhinovirus was isolated from another household member.
Table 1 Demographic and other characteristics of the index cases and household members
Variable Mask arm (% and 95% CI) Control arm (% and 95% CI)
Index case (number) 123 122
Gender (male) 56/123
45.5% (37.0% to 54.3%)
45/122
36.9% (28.8% to 45.7%)
Age (mean) 40.2 (37.6 to 42.8) 39.7 (37.3 to 42.0)
Education (undergraduate/postgraduate) 78/123
63.4% (54.6% to 71.4%)
74/122
60.7% (51.8% to 68.9%)
Smoker (current/ex) 29/123
23.6% (16.9% to 31.8%)
26/122
21.3% (15.0% to 29.4%)
Pre-existing illness* 21/123
17.1% (16.2% to 31.0%)
16/122
13.1% (8.2% to 20.2%)
Influenza vaccination (yes) 5/123
4.1% (1.7% to 9.2%)
5/122
4.1% (1.8% to 9.2%)
Hand washing (most/all times) 98/123
79.7% (71.7% to 85.8%)
109/122
89.3% (82.6% to 93.7%)
Average hour of home stay† 16.6 (15.9 to 17.3) 16.6 (15.9 to 17.3)
Average hour mask wearing† 4.4 (3.9 to 4.9) 1.4 (0.9 to 1.8)
Household (members) 302 295
Number of household per arm 2.5 2.4
Gender (male) 149/302
49.3% (43.4% to 24.6%)
168/295
56.9% (51.6% to 62.9%)
Influenza vaccination (yes)‡ 22/298
7.4% (4.9% to 10.9%)
30/285
10.5% (7.1% to 14.6%)
Age (mean) 38.3 (36.0 to 40.5) 36.4 (34.1 to 38.8)
*Includes asthma, chronic obstructive pulmonary disease, diabetes, ischaemic heart disease, immune-compromised and others.
†Variable was created by taking average hours over the trial period.
‡Missing data for 14 cases.
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Table 2 Number and proportion of household members reporting primary outcomes, by randomisation arm and intention-to-treat analysis (n=597)*
CRI No (rate person-days) RR (95% CI) ILI No (rate person-days)
Laboratory-confirmed viral
respiratory infections
No (rate person-days) RR (95% CI)
Mask arm† 4/2098 (1.91/1000) 0.65 (0.18 to 2.29) 1/2098 (0.48/1000) 0.32 (0.03 to 3.11) 1/2098 (0.48/1000) 0.97 (0.06 to 15.5)
Control arm‡ 6/2036 (2.95/1000) Ref 3/2036 (1.47/1000) Ref 1/2036 (0.49/1000) Ref
*Household members (mask arm 302 and control arm 295).
†Intracluster correlation coefficient is <0.001.
‡Intracluster correlation coefficient is <0.001.
CRI, clinical respiratory illness; ILI, influenza-like illness; RR, relative risk.
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Kaplan-Meier curves showed no significant differences in
the outcomes between two arms (p>0.050; figure 2).
The duration of contact of index cases with household
members was 10.4 and 11.1 hours in the mask and
control arms, respectively. On average, participants in
the mask arm used a mask for 4.4 hours, while partici-
pants in the control arm used a mask for 1.4 hours. In a
univariable Cox model, only the age of the household
contact was significantly associated with the CRI
(table 3). There was no association between mask use by
the index cases and rates of infectious outcomes in
household members (table 3). Although the risks of CRI
(RR 0.61, 95% CI 0.18 to 2.13), ILI (RR 0.32, 95% CI
0.03 to 3.13) and laboratory-confirmed viral infections
(RR 0.97, 95% CI 0.06 to 15.54) were lower in the mask
arm, the difference was not statistically significant.
Tables 4 and 5 show a sensitivity analysis comparing
outcomes among household members of index cases
using a mask (mask group) with those of index cases
who did not use a mask (no-mask group). Overall, 159
index cases (65%) used a mask during the trial period
including 43 participants from the control arm. Three
hundred and eighty-seven household members were
included in the mask group and 210 were included in
the no-mask group. Rates of all outcomes were lower in
the mask group, and CRI was significantly lower in the
contacts of the mask group compared with the contacts
of the no-mask group. The Kaplan-Meier curves
(figure 3) showed a significant difference in the rate of
CRI among the mask and no-mask groups (p 0.020).
After adjusting for the age of household contacts,
the risk of CRI was 78% lower in the contacts of the
mask group (RR 0.22, 95% CI 0.06 to 0.86), compared
with contacts of the no-mask group. Although the risks
of ILI (RR 0.18, 95% CI 0.02 to 1.73) and laboratory-
confirmed viral respiratory infections (RR 0.11, 95% CI
0.01 to 4.40) were also lower in the mask group, the
difference was not statistically significant.
DISCUSSION
Masks are commonly recommended as source control for
patients with respiratory infections to prevent the spread
of infection to others,2 3 but data on the clinical efficacy of
this approach are sparse. We did not find a significant
benefit of medical masks as source control, but rates of
CRI and ILI in household members were consistently
lower in the mask arm compared with the control arm.
The study was underpowered to detect a statistically signifi-
cant difference. The additional analysis by actual mask use
showed significantly lower rates of CRI in the mask group
compared with the no-mask group, suggesting that larger
trials should be conducted to further examine the efficacy
of masks as source control.
Our findings are consistent with previous research in
community and household settings, where the efficacy
of masks as source control was measured. Until now,
only one RCT has been conducted in the community
setting to examine the role of masks in preventing
spread of infection from wearers.3 Canini and collea-
gues conducted an RCT in France during the 2008–
2009 influenza season and randomised index patients
into medical mask (52 households and 148 contacts)
and control arms (53 households and 158 contacts).
ILI was reported in 16.2% and 15.8% of contacts in the
intervention and control arms, respectively, and the dif-
ference was not statistically significant (mean difference
0.40%, 95% CI −10% to 11%, p=1.00). The trial was
concluded early due to low recruitment and the subse-
quent influenza A (H1N1)pdm09 pandemic.13 In add-
ition, masks were also used by index cases and
household members in some community-based RCTs
with mixed interventions.14 15 Cowling and colleagues
conducted two RCTs in Hong Kong to examine the
efficacy of masks, and index cases were randomised
into medical mask, medical mask plus hand hygiene,
hand hygiene and control arms. Both index cases and
household members used masks. The rates of
laboratory-confirmed influenza and ILI were the same
in the intervention and control groups in the
intention-to-treat analysis.14 However, in the second trial,
mask use with hand hygiene was protective in household
contacts when the intervention was applied within
36 hours of onset of symptoms in the index case (OR
0.33, 95% CI 0.13 to 0.87).15 Since masks were used by
sick patients and their household members in these
studies, the effect of mask being ‘source control’ is more
difficult to quantify precisely.
Table 3 HRs from shared frailty Cox proportional hazards model for household members in masks versus control arms
(n=597)*
CRI
HR (95% CI)†
ILI
HR (95% CI)†
Laboratory-confirmed
viral respiratory infections
HR (95% CI)†
Masks arm (index case) 0.61 (0.18 to 2.13) 0.32 (0.03 to 3.13) 0.97 (0.06 to 15.54)
Control arm (index case) Ref Ref Ref
Age (household) 1.03 (1.01 to 1.05)
*Household members (mask arm 302 and control arm 295).
†Multivariate analysis was performed as there were 10 cases of CRI and age was also significant in the univariate analysis. Multivariate
analyses were not performed for ILI and laboratory-confirmed viral respiratory infections due to the low number of cases.
CRI, clinical respiratory illness; ILI, influenza-like illness.
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Table 4 Number and proportion of participants reporting primary outcomes, by mask versus no-mask groups (n=597)*
CRI No (rate
person-days) RR
ILI
No (rate
person-days) RR
Laboratory-confirmed viral respiratory
infections
No (rate person-days) HR†
Mask group 3/2694 (1.11/1000) 0.23 (0.06 to 0.88) 1/2694 (0.37/1000) 0.18 (0.02 to 1.71) 0/2694 (0/1000) 0.11 (0.01 to 4.40)
No-mask group 7/1440 (4.86/1000) Ref 3/1440 (2.08/1000) Ref 2/1440 (0.70/1000) Ref
*Household members (mask group 387 and no-mask group 210).
†Calculated through Cox PH methods.
CRI, clinical respiratory illness; ILI, influenza-like illness; PH, proportional hazards; RR, relative risk.
Table 5 HRs from shared frailty Cox proportional hazards model for mask versus no-mask groups (no randomization; n=597)*
CRI
HR (95% CI)†
ILI
HR (95% CI)†
Laboratory-confirmed viral
respiratory infections
HR (95% CI)†
Masks group (index case) 0.22 (0.06 to 0.86) 0.18 (0.02 to 1.73) 0.11 (0.01 to 4.40)
No-mask group (index case) Ref Ref Ref
Age (household) 1.03 (1.00 to 1.06)
Bold values are statistically significant results.
*Household members (mask group 387 and no-mask group 210).
†Multivariate analysis was performed as there were 10 cases of CRI and age was also significant in the univariate analysis. Multivariate analyses were not performed for ILI and
laboratory-confirmed viral respiratory infections due to the low number of cases.
CRI, clinical respiratory illness; ILI, influenza-like illness.
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Masks are not designed for respiratory protection and
are commonly used in the healthcare setting to prevent
spread of infections from the wearer, whether worn by a
sick patient or well staff member.1 3 One such use is the
wearing of masks by well surgeons and other OT staff to
protect patients from contamination during surgery.
Presumably, the exhaled pathogen load would be much
higher in a sick patient compared with a well surgeon,
and therefore the use of a mask for source control in
sick patients may have more benefit than OT use of
source control.
This study has some limitations. The sample size was
small and the study may have been underpowered to
detect a statistically significant difference in outcome in
the intention-to-treat analysis. Post hoc analysis, however,
showed a potential benefit of medical masks for source
control. It is possible that infection transmission may
have occurred during meal times (when patients were
not required to wear a mask). This would have the effect
of biasing the results towards the null. In the sample size
calculations, we assumed a 16–20% attack rate of CRI in
the control arm, based on the results of a previously
published household mask trial.17 However, the second-
ary attack rates were much lower in this study which
might be due to testing only symptomatic cases.
In a univariable Cox model, only the age of household
contact was significantly associated with the CRI. All
other variables were uniformly distributed among the
study arms, so we only adjusted for the age of the house-
hold contact in the analysis of CRI as an outcome.
Multivariate analyses were not performed for ILI and
laboratory-confirmed viruses. However, some variables
may have an impact on the number of events. For
example, the rates of hand hygiene were higher among
the ‘control’ arm compared with the mask arm (109/122,
89.3% vs 98/123, 79.7%), which may have had an impact
on the number of outcome events. Owing to the low event
rates and non-significant difference of hand hygiene
among the two arms, we did not adjust for hand hygiene
in any analysis. Further, inclusion of hand hygiene in the
model did not change the HR. Finally, post hoc analyses
are potentially biased due to loss of randomisation and it
was added as a sensitivity analysis in this study because of
deviations from protocol in mask wearing.
Despite a lack of evidence, most health organisations
and countries recommend the use of masks by sick
patients as source control.1 2 Masks are used commonly
by patients with TB, although clinical trials have not
been conducted for this indication. There is a need to
conduct larger trials to confirm the suggestion of
benefit in our study. If source control is effective in redu-
cing hospital transmission of infection, this may have a
practical benefit to mitigate the problem of poor com-
pliance with mask wearing among well HCWs.3
Compliance with any intervention for someone who is
well and asymptomatic is far more challenging than
compliance in people who are unwell,29 so source
control may have an important role in hospital infection
control. Reducing the transmission of respiratory patho-
gens by source patients could also have further benefits
in the community in preventing transmission of infec-
tion to close contacts such as those in the same house-
hold, and should be studied further.
Figure 3 Survival curves for mask versus no-mask group
(3A–C). The scale used in Kaplan Meier curves represents
only a fraction of the 0–1 range.
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